Registered Clinical Research on Amyotrophic Lateral Sclerosis (NCT07143656)

BioCells Medical is officially listed as sponsor and clinical site of a multicenter retrospective observational registry registered on ClinicalTrials.gov (NCT07143656).This registry underscores our contribution to global research on the progression of neurodegenerative disorders, specifically amyotrophic lateral sclerosis (ALS).

About the Study

• Population: Adults aged 18–70 with confirmed ALS or motor neuron disease.

• Innovation: Analysis of seven years of real-world longitudinal data, focusing on disease progression via the ALS Functional Rating Scale–Revised (ALSFRS‑R).

• Design: Retrospective observational registry involving 36 patients.

• Assessments: ALSFRS-R scores; secondary outcomes include survival, ventilatory decline, and correlations with biomarkers like neurofilament light chain and cytokines.
  

Why This Matters

ALS remains one of the most devastating neurodegenerative conditions with limited treatment options.Through this registry, BioCells Medical advances understanding of ALS progression and biomarker correlations, enriching the evidence base for future therapeutic strategy development.

Global Recognition

Listing on ClinicalTrials.gov, the world’s largest clinical research registry maintained by the U.S. National Library of Medicine, establishes BioCells Medical as a credible contributor to ALS research on the international stage.